A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High-Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)

This study is being done to answer the following question: Can we lower the chance of your bladder cancer growing or spreading by using one type of chemotherapy instilled in the bladder, Gemcitabine and Docetaxel, instead of the usual therapy? The usual approach for patients who are not in a study is treatment with Transurethral surgery of bladder tumor (TURBT) followed by instillations of Bacillus Calmette-Guerin (BCG) immunotherapy into the bladder via a catheter. We are doing this study because we want to find out if this approach is better or worse than the usual approach for your bladder cancer.

Are you Eligible? (Inclusion Criteria)

• Are you 18 years of age or older? Have you been diagnosed with non-muscle invasive bladder cancer, and have not previously received BCG treatment? Are you able to make regularly scheduled visits to the clinic for treatment and examinations?